Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
Rhea-AI Summary
Metagenomi Therapeutics (Nasdaq: MGX) announced that President and CEO Jian Irish, Ph.D., M.B.A., will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026, at 7:35 a.m. ET. The presentation will be accessible via the Investors section of the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – MGX
In the May 28 session, MGX gained 3.70%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Earnings update | Positive | +0.0% | Reported Q1 2026 results, MGX-001 timelines, and cash runway through 4Q 2027. |
| Apr 16 | Scientific publication | Positive | +0.0% | Nature Structural & Molecular Biology paper on compact CRISPR nuclease MG119-28. |
| Mar 05 | Full-year earnings | Positive | -8.1% | Full-year 2025 results, MGX-001 pre-IND progress, and cash runway into 4Q 2027. |
| Feb 23 | Conference appearance | Neutral | +6.4% | Announcement of fireside chat at 46th Annual TD Cowen Healthcare Conference. |
| Jan 12 | Corporate update | Positive | -2.2% | Corporate name change and milestones, including MGX-001 durability and 4Q 2026 IND/CTA plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
MGX has mixed reactions to news: conference and scientific visibility pieces have sometimes aligned with gains, while broader business and outlook updates have twice coincided with post-news declines.
Over the last six months, MGX has focused on building visibility and advancing its pipeline. Earnings updates in March 2026 and May 2026 highlighted cash runway into 4Q 2027 and plans for MGX-001 regulatory submissions in 4Q 2026. Scientific validation of MG119-28 in April 2026 and prior conference appearances, such as TD Cowen in March 2026, show a pattern of investor outreach similar to today’s Jefferies participation.
Key Terms
in vivo genome editing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 4, 2026, at 7:35 a.m. ET.
The fireside chat presentation will be made available on the “News & Events” page in the Investors section of the Company’s website at https://ir.metagenomi.co/news-events/events.
About Metagenomi Therapeutics
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel CRISPR gene-editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, insertion and correction.
MGX-001, the Company’s lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile with best-in-class treatment potential, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children, potentially enabling a new standard of care for the treatment of hemophilia A. The Company is also currently pursuing indications leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co/.
Investor Contact:
Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com
